论文部分内容阅读
目的观察促红细胞生成素治疗肿瘤相关性慢性贫血患者的疗效,探讨其临床价值。方法选择台州市第一人民医院于2012年2月—2016年2月收治的80例肿瘤相关性慢性贫血患者入选本研究,均符合诊断标准,无明显药物禁忌,按照随机数字表随机分为2组,每组40例。对照组在常规治疗基础上采用静脉滴注蔗糖铁治疗,观察组在常规治疗基础上给予皮下注射促红细胞生成素治疗,比较2组血液指标变化、KPS评分疗效、血液学指标疗效和不良反应。结果治疗后,观察组血各液学指标改善情况明显优于照组,差异有统计学意义(P<0.05);2组患者治疗后KPS量表评分疗效总有效率观察组明显优于对照组,差异有统计学意义(P<0.05);治疗后观察组有效率为95.0%,对照组有效率为47.5%,观察组有效率明显高于对照组,差异有统计学意义(P<0.05)。观察组总不良反应发生为12.50%,显著低于对照组37.50%,差异有统计学意义(P<0.05)结论促红细胞生成素治疗肿瘤相关性贫血疗效确切,不良反应相对较少,值得临床推广应用。
Objective To observe the therapeutic effect of erythropoietin on patients with tumor-associated chronic anemia and to explore its clinical value. METHODS: Tumor-associated chronic anemia patients admitted to the First People’s Hospital of Taizhou City from February 2012 to February 2016 were enrolled in this study. All of them were in accordance with the diagnostic criteria and had no obvious contraindications. Randomly divided into 2 Group, 40 cases in each group. The control group was treated with intravenous drip infusion of sucrose iron on the basis of conventional treatment. The observation group was given subcutaneous injection of erythropoietin on the basis of routine treatment. The changes of blood index, curative effect of KPS, hematological indexes and adverse reactions were compared between two groups. Results After treatment, the improvement of blood test in observation group was significantly better than that in control group (P <0.05). The total effective rate of KPS in two groups was significantly better than that in control group , The difference was statistically significant (P <0.05); after treatment, the effective rate of the observation group was 95.0%, the effective rate of the control group was 47.5%, the observation group effective rate was significantly higher than the control group, the difference was statistically significant (P <0.05) . The total adverse reaction in the observation group was 12.50%, which was significantly lower than that in the control group (37.50%), the difference was statistically significant (P <0.05) Conclusion Erythropoietin treatment of tumor-related anemia is effective, the adverse reactions are relatively small, worthy of clinical promotion application.